Delphia (USA)’s Kezar Life Sciences KZR Stock Holding History

Delphia (USA)’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,014	Closed	-$71.4K	–	300
2022 Q4	$71.4K	Sell	1,014 -51	-5%	-$3.78K	0.08%	261
2022 Q3	$92K	Buy	+1,065	New	+$103K	0.11%	251

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Delphia (USA)'s KZR Position: Q1 2023 in Review

Delphia (USA) sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 1,014 shares — an estimated $71.4K sold.

Delphia (USA) first reported a position in KZR in Q3 2022 and held it in 2 quarters. The position peaked at $92K in Q3 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

Delphia (USA) reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
Delphia (USA) sold 1,014 Kezar Life Sciences shares in Q1 2023, an estimated $71.4K.
Delphia (USA) first reported a position in Kezar Life Sciences in Q3 2022 and held it in 2 quarters.
Delphia (USA)'s Kezar Life Sciences position peaked at $92K in Q3 2022.
136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Delphia (USA)'s 13F filing for Q1 2023, filed 15 May 2023.